Conversions from Clozapine to other Antipsychotic Drugs

Archives of General Psychiatry

Volumn 52, Issue 12, 1995, Pages 1071-1072

  Baldessarini, Ross J ^a   Gardner, David M ^b   Garver, David L ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 4 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; THIORIDAZINE;

DATA ANALYSIS; HIGH RISK POPULATION; HUMAN; LETTER; PSYCHOSIS; RISK ASSESSMENT; RISK MANAGEMENT;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMAN; RECEPTORS, DOPAMINE; RISK FACTORS; SULPIRIDE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THIORIDAZINE;

EID: 0028807660     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1995.03950240089014     Document Type: Letter

References (21)

1. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151: 825–835.
2. Ekblom B, Eriksson K, Lindstrom LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology. 1984;83: 293–294.
3. Perenyi A, Kuncz E, Bagdy G. Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology. 1986;86:244.
4. Eklund K. Supersensitivity and clozapine withdrawal. Psychopharmacology. 1987;90:135.
5. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry. 1991;52: 346–348.
6. Parsa MA, Al-Lahham YH, Ramirez JF, Meltzer HY. Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol. 1993;13: 154–155.
7. Abuzzahab FS, Gillund JM. Clozapine and risperidone in schizophrenia. In: ACNP Annual Meeting Abstracts. Nashville, Tenn: American College of Neuropsychopharmacology;1994;33:225.
8. Gilbert PL, Harris MJ, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52: 173–188.
9. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995;52: 189–192.
10. Dickson R, Williams R, Dalby JT. Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry. 1994;39:184.
11. Mok H, Yatham LN. Response to clozapine as a predictor of risperidone response in schizophrenia. Am J Psychiatry 1994;151: 1393–1394.
12. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324: 746–754.
13. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology. 1992;108: 338–344.
14. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 1993;9: 117–124.
15. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli D. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991;350: 610–614.
16. O'Malley KL, Harmon S, Tang L, Todd RD. The rat D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biologist. 1992;4: 137–146.
17. Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatmentrefractory mood disorders. J Clin Psychiatry. 1994;55(suppl B): 91–93.
18. Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism: receptor occupancy profile and pharmacologic activity. J Clin Psychiatry. 1994;55(suppl 5): 5–12.
19. Wolf ME, Roth RH. Autoreceptor regulation of dopamine synthesis. Ann NY Acad Sci. 1990;604: 323–342.
20. Ichikawa J, Meltzer HY. Differential effects of repeated treatment with haloperidol and clozapine and dopamine release and metabolism in the striatum and the nucleus accumbens. J. Pharmacol Exp Ther. 1991;256: 348–357.
21. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harvard Rev Psychiatry. 1993;1: 131–144.